MedTrace Logo

OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy

NCT06466382 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-05-05

No results posted yet for this study

Summary

The long-term goal of this research project is to demonstrate whether HRD negative (HPDneg) patients benefit when additional multi-modal biological tumor information is incorporated into the molecular tumor board (mTB) treatment recommendation process.

Conditions

  • Ovarian Neoplasm Epithelial
  • Fallopian Tube Neoplasms
  • Ovarian Endometrioid Carcinoma
  • High-grade Serous Ovarian Carcinoma (HGSOC)

Interventions

OTHER

Treatment recommendation by molecular tumorboard (mTB) based on tumor profiling

The intervention studied is a treatment recommendation by a specialized molecular tumorboard (mTB). This recommendation is based on an MSR which is created by TP, i.e., molecular analysis of clinical specimens, obtained from the individual participant. TP, a technology platform of several precision-cancer profiling domains, combines and rates the most efficient drugs/ experimental treatments for an individual ovarian cancer patient independent of standard of care. The usability in clinical practice of this recommendation will be tested. It should support the clinical decision of the treating oncologists and patients to choose the best possible therapy for the individual patient.

DRUG

Carboplatin / Paclitaxel Chemotherapy

2 cycles of chemotherapy with carboplatin AUC5 3-weekly and paclitaxel 175 mg/m2 3-weekly or carboplatin AUC2 weekly and Paclitaxel 60-80mg/m2 weekly

Sponsors & Collaborators

  • Tumor Profiler Center Switzerland

    collaborator UNKNOWN

  • Swiss GO Trial Group

    lead NETWORK

Principal Investigators

  • Viola Heinzelmann-Schwarz, Prof. · University Hospital Basel, Head Women's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-31
Primary Completion
2027-03-31
Completion
2028-09-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06466382 on ClinicalTrials.gov